Literature DB >> 30511049

A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus.

Lauren E Mellor-Crummey1, Jordan E Lake1,2, Holly Wilhalme2, Chi-Hong Tseng2, Philip M Grant3, Kristine M Erlandson4, Jennifer C Price5, Frank J Palella6, Larry A Kingsley7, Matthew Budoff8, Wendy S Post9, Todd T Brown9.   

Abstract

BACKGROUND AND AIM: Non-alcoholic fatty liver disease (NAFLD) is common among HIV-infected (HIV+) adults. The Liver Fat Score (LFS) is a non-invasive, rapid, inexpensive diagnostic tool that uses routine clinical data and is validated against biopsy in HIV-uninfected (HIV-) persons. CT liver-to-spleen (L/S) attenuation ratio is another validated method to diagnose NAFLD. We compared NAFLD prevalence using the LFS versus L/S ratio among Multicenter AIDS Cohort Study participants to assess the LFS's performance in HIV+vs. HIV-men.
METHODS: In a cross-sectional analysis of men reporting<3 alcoholic drinks daily (308 HIV+, 218 HIV-), Spearman correlations determined relationships between LFS and L/S ratio by HIV serostatus. Multivariable regression determined factors associated with discordance in LFS- and L/S ratio-defined NAFLD prevalence.
RESULTS: NAFLD prevalence by LFS and L/S ratio were 28%/15% for HIV+men and 20%/19% for HIV-men, respectively. Correlations between LFS and L/S ratio were weaker among HIV+than HIV-men, but improved with increasing BMI and exclusion of HCV-infected men. LFS and L/S ratio discordance occurred more frequently and across BMI strata among HIV+men, but predominantly at BMI<30 kg/m2 among HIV-men. In multivariate analysis, only lower total testosterone levels were significantly associated with discordance.
CONCLUSION: NAFLD prevalence was similar by LFS and L/S ratio identification among HIV-men, but dissimilar and with frequent discordance between the two tests among HIV+men. As discordance may be multifactorial, biopsy data are needed to determine the best non-invasive diagnostic test for NAFLD in HIV+persons.

Entities:  

Keywords:  Hepatic steatosis; Human immunodeficiency; Non-alcoholic steatohepatitis

Year:  2018        PMID: 30511049      PMCID: PMC6269145          DOI: 10.21767/2575-7733.1000045

Source DB:  PubMed          Journal:  J Clin Gastroenterol Hepatol        ISSN: 2575-7733


  25 in total

Review 1.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

Review 2.  Hypogonadism and non-alcoholic fatty liver disease.

Authors:  Gesthimani Mintziori; Pavlos Poulakos; Christos Tsametis; Dimitrios G Goulis
Journal:  Minerva Endocrinol       Date:  2016-11-23       Impact factor: 2.184

3.  Sex hormones, insulin resistance, and diabetes mellitus among men with or at risk for HIV infection.

Authors:  Anne K Monroe; Adrian S Dobs; Xiaoqiang Xu; Frank J Palella; Lawrence A Kingsley; Mallory D Witt; Todd T Brown
Journal:  J Acquir Immune Defic Syndr       Date:  2011-10-01       Impact factor: 3.731

4.  Sex differences in the association of HIV infection with hepatic steatosis.

Authors:  Ani Kardashian; Yifei Ma; Rebecca Scherzer; Jennifer C Price; Monika Sarkar; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan M Noworolski; Phyllis C Tien
Journal:  AIDS       Date:  2017-01-28       Impact factor: 4.177

5.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

Authors:  G Behrens; A Dejam; H Schmidt; H J Balks; G Brabant; T Körner; M Stoll; R E Schmidt
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

6.  The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis.

Authors:  Anneloes E Bohte; Jochem R van Werven; Shandra Bipat; Jaap Stoker
Journal:  Eur Radiol       Date:  2010-07-31       Impact factor: 5.315

7.  Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease.

Authors:  Chung-Huang Tsai; Tsai-Chung Li; Cheng-Chieh Lin
Journal:  South Med J       Date:  2008-09       Impact factor: 0.954

8.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

9.  Risk factors for fatty liver in the Multicenter AIDS Cohort Study.

Authors:  Jennifer C Price; Eric C Seaberg; Rachel Latanich; Matthew J Budoff; Lawrence A Kingsley; Frank J Palella; Mallory D Witt; Wendy S Post; Chloe L Thio
Journal:  Am J Gastroenterol       Date:  2014-03-18       Impact factor: 10.864

10.  Non-invasive score identifies ultrasonography-diagnosed non-alcoholic fatty liver disease and predicts mortality in the USA.

Authors:  Ching-Lung Cheung; Karen S L Lam; Ian C K Wong; Bernard M Y Cheung
Journal:  BMC Med       Date:  2014-09-10       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.